^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CGX1321

i
Company:
Curegenix
Drug class:
Wnt signalling pathway inhibitor, PORCN inhibitor
Phase 1b
Curegenix Inc.
Recruiting
Last update posted :
01/26/2022
Initiation :
02/01/2016
Primary completion :
03/01/2023
Completion :
03/01/2023
BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
|
BRAF V600E • BRAF V600
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321